Loxo Oncology: Loxo Oncology at Lilly announces updated data from phase 1/2 BRUIN trial of pirtobrutinib in patients with CLL, SLL & MCL

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company announced updated clinical data from the pirtobrutinib global phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic